Publikationen 2026

Kunadt D, Zukunft S, Röllig C, Metzelder S, Burchert A, Wagner-Drouet E, Kriege O, Schliemann C, Stelljes M, Ronnacker J, Bethge W, Weller JF, Steffen B, Bug G, Kouidri K, Baldus C, Fransecky L, Sala E, Platzbecker U, Metzeler K, Kayser S, Hilgendorf I, Hochhaus A, Brümmendorf TH, Jost E, Doleschall AD, Schroeder T, Kaivers J, Kordelas L, Holtick U, Unglaub JM, Sauer T, Jäger PS, Kobbe G, Stauffer E, Tischer J, Herold T, Steiner N, Nachbaur D, Kröger N, Frietsch JJ, Kraus S, Einsele H, Hänel M, Schaffrath J, Krüger W, Brandenburg A, Holderried TAW, Reinhardt L, Maulhardt M, Thiede C, Bornhäuser M, Schetelig J, Middeke JM, Stölzel F; German Cooperative Transplant Study Group and Study Alliance Leukemia (SAL). Treatment sequence with gilteritinib and allogeneic haematopoietic stem cell transplantation in relapsed/refractory FMS-like tyrosine kinase 3 (FLT3)-mutated acute myeloid leukaemia patients: A multicentre real-world study. Br J Haematol. 2026 Aug 18. doi: 10.1111/bjh.70735. Epub ahead of print. PMID: 42610785

Rocke P, Tandetzky L, Wolff D, Egger-Heidrich K, Heidenreich D, Schaefer-Eckart K, Wagner-Drouet E, Frietsch JJ, Hochhaus A, Hilgendorf I. Comorbid conditions after allogeneic haematopoietic stem cell transplantation in young adults in Germany-A prospective, multicentre trial. Br J Haematol. 2026 Aug 10. doi: 10.1111/bjh.70738. Epub ahead of print. PMID: 42575722.

Gimbel M, Stoll C, Fuxius S, Prott FJ, Münstedt K, Zomorodbakhsch B, Wittmann S, Kastrati K, Hübner J. Efficacy of a Decision-Making Aid About Homeopathy in Patients With Cancer: A Single-Arm, Pre-Post Observational Study. Health Sci Rep. 2026 Jul 30;9(8):e72943. doi: 10.1002/hsr2.72943. PMID: 42534408; PMCID: PMC13420187

Ciarlo, G., Oehlrich, M. & Huebner, J. Online cancer forums and complementary and alternative medicine in cancer care: effects of ehealth literacy and psychological distress on use and attitudes. Support Care Cancer 34, 827 (2026). https://doi.org/10.1007/s00520-026-11049-3

Ciarlo G, Josfeld L, Hübner J. The Needs of Patients with Cancer Interested in Complementary and Alternative Medicine with Respect to the Physician's Attitude and Behaviour. Cancer Invest. 2026 Aug;44(7):755-768. doi: 10.1080/07357907.2026.2675656. Epub 2026 May 26. PMID: 42186825

Ussmann J, Jentzsch M, Schwind S, Herling M, Vučinić V, Merz M, Hilgendorf I, Hochhaus A, Platzbecker U, Metzeler KH, Franke GN. Relapse risk after FLAMSA RIC based allogeneic hematopoietic stem cell transplantation in heavily pretreated AML patients. Bone Marrow Transplant. 2026 Jul 15. doi: 10.1038/s41409-026-02960-8. Epub ahead of print. PMID: 42457984

Cortes JE, Sasaki K, Kim DW, Hughes TP, Etienne G, Mauro MJ, Hochhaus A, Lang F, Heinrich MC, Breccia M, Deininger M, Goh YT, Janssen JJWM, Talpaz M, de Soria VGG, le Coutre P, DeAngelo DJ, Damon A, Cacciatore S, Polydoros F, Agrawal N, Rea D. Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after ≥1 prior tyrosine kinase inhibitor: 2-year follow-up results. Leukemia. 2024 Jul;38(7):1522-1533. doi: 10.1038/s41375-024-02278-8. Epub 2024 May 16. PMID: 38755421; PMCID: PMC11217003

Ruhe J, Hochhaus A, Wolf G, Hammersen J: Hämatologische Erkrankungen und Niere. Nephrologie aktuell 2026; 30: 264–274

Issa GC, Larson RA, Hughes TP, Hochhaus A, Takahashi N, Bombaci F, Wang J, Kim DW, Kim DDH, Mayer J, Goh YT, Le Coutre P, Kim I, Etienne G, Andorsky D, Gu E, Zhang Y, McCulloch T, Agrawal N, Jinwal R, Damon A, Sadek I, Cortes JE. Favorable tolerability of asciminib versus ATP-competitive tyrosine kinase inhibitors in the ASC4FIRST study of newly diagnosed patients with chronic-phase chronic myeloid leukemia. Haematologica. 2026 Jul 2. doi: 10.3324/haematol.2025.300145. Epub ahead of print. PMID: 42389818

Ghazvini Zadegan F, Stanko C, Fiedler F, Ölsner L, Özcan SG, Schütt J, Schnöder TM, Sbirkov Y, Szymanski L, Stengel S, Dittrich P, Müller JP, Heidel FH, Hochhaus A, Scholl S, Schnetzke U, Brioli A, Schenk T. Am80 (tamibarotene) and ATRA induce highly similar molecular responses and myeloid differentiation in non-APL AML, enhanced by LSD1/GCN5 inhibition and increased RARA expression. BMC Cancer. 2026 Jun 27;26(1):777. doi: 10.1186/s12885-026-16388-2. PMID: 42365243; PMCID: PMC13309949

Vogel A, Ben Khaled N, Ramirez JR, Marhenke S, Siegler G, Siebler J, Lindig U, Schwartz G, Schultheiss M, Mueller T, Simon H, De Toni EN, Karl D, Al-Batran SE, Saborowski A. Nivolumab in combination with lenvatinib in unresectable hepatocellular carcinoma: The IKF-t006/IMMUNIB translational phase-2 study. Eur J Cancer. 2026 Jun 3;243:116847. doi: 10.1016/j.ejca.2026.116847. Epub ahead of print. PMID: 42284972

Bagdonas S, Schäfer L, Wolf C, Hübner J: The financial burden resulting from complementary and alternative medicine in oncology care. BMC Complement Med Ther 26, 205 (2026). https://doi.org/10.1186/s12906-026-05417-z

Arends J, Rubin D, Mathies V, Mensger C, Hübner J: Aktualisierte S3-Leitlinie „Klinische Ernährung in der Onkologie“. Forum 41, 216–220 (2026). https://doi.org/10.1007/s12312-026-01557-y

Brock H, Mehnert-Theuerkauf A, Kreilinger D, Strauß B, Schunke R, Grüner P, Hochhaus A, Stolzenburg J, Lordick F, Springer F: Wirksamkeit eines digitalen Unterstützungsangebots in der onkologischen Routineversorgung. Forum 41, 231–233 (2026). https://doi.org/10.1007/s12312-026-01560-3

Eigendorff F, Görke F, Zeremski V, Wollnitza S, Shumilov E, Lenz G, et al. Response-adapted consolidation and salvage strategies in secondary central nervous system lymphoma: Insights from a multicentre cohort. Br J Haematol. 2026;00:1–10. https://doi.org/10.1111/bjh.70633

Ossami Saidy A, Boumendil A, Dreger P, Stella F, Ram R, Kröger N, Castagna L, Pabst T, Wulf GG, Martin Garcia-Sancho A, Solano C, Stelljes M, Reinhardt HC, Forcade E, von Bonin M, Hilgendorf I, Martínez López J, Bethge W, Bazarbachi A, Sureda A, Schmitz N, Glass B; GOCART initiative; Lymphoma Working Party (LWP) of the EBMT. The impact of IPI risk factors on CAR T-cell therapy or allogeneic stem cell transplantation for treatment of relapsed or refractory large B-cell lymphoma (LBCL). Bone Marrow Transplant. 2026 Jun 19. doi: 10.1038/s41409-026-02913-1. Epub ahead of print. PMID: 42321403

Arends J, Rubin D, Mathies V, Mensger C, Hübner J: Aktualisierte S3-Leitlinie „Klinische Ernährung in der Onkologie“. Forum 41, 216–220 (2026). https://doi.org/10.1007/s12312-026-01557-y

Bagdonas S, Schäfer L, Wolf C, Hübner J. The financial burden resulting from complementary and alternative medicine in oncology care. BMC Complement Med Ther. 2026 Jun 6;26(1):205. doi: 10.1186/s12906-026-05417-z. PMID: 42249373; PMCID: PMC13242131

Grüll S, Huebner J, Ciarlo G. Acculturation, resilience, and healthcare trust in migrant populations: an equity perspective. Arch Public Health. 2026 Jun 4;84(1):126. doi: 10.1186/s13690-026-01946-8. PMID: 42243944

Arndt Vogel, Najib Ben Khaled, Javier Ruiz Ramirez, Silke Marhenke, Gabriele Siegler, Jürgen Siebler, Udo Lindig, Gregory Schwartz, Michael Schultheiss, Tobias Mueller, Henry Simon, Enrico N. De Toni, Daniel Karl, Salah-E. Al-Batran, Anna Saborowski,Nivolumab in combination with lenvatinib in unresectable hepatocellular carcinoma: the IKF-t006/IMMUNIB translational phase-2 study, European Journal of Cancer, 2026, 116847, ISSN 0959-8049, https://doi.org/10.1016/j.ejca.2026.116847

Wickel J, Ceanga M, Vlad B, von Stackelberg N, Tochoedo NR, Schulz D, Yomade O, Dudziak D, Geis C. Therapeutic effect of T-cell engager in two patients with autoimmune neuropathy. Nat Commun. 2026 May 30;17(1):4816. doi: 10.1038/s41467-026-73819-1. PMID: 42218153; PMCID: PMC13222356

Ernst P, Rachow T, Henn S, Hammersen JF, Dittrich S, Heßmer A, Hillig A, Heßmer A, Hochhaus A. Residential radon exposure and lung cancer histology and stage: a population-based ecological study in Central Germany. J Cancer Res Clin Oncol. 2026 May 31. doi: 10.1007/s00432-026-06524-7. Epub ahead of print. PMID: 42218725

Falkenried J, Ahmadi E, Davitian K, Hübner J. The relationship between patient activation measure and use of complementary and alternative medicine in oncology patients. Patient Educ Couns. 2026 Apr 18;149:109650. doi: 10.1016/j.pec.2026.109650. Epub ahead of print. PMID: 42019172

Manz K, Kobrosly M, Crodel CC, Al-Ali H, Isfort S, Kleppe D, Neubert M, Schnöder TM, Rogalski I, Jilg S, Stauch T, Hoffmann W, Krüger WH, Krönke J, Hochhaus A, Homann C, Heidel FH. Value of functional iron parameters in diagnostic re-assessment of MPN: refinement of iron-deficiency markers by zinc protoporphyrin (ZPP). Ann Hematol. 2026 May 23;105(6):294. doi: 10.1007/s00277-026-07077-y. PMID: 42176009; PMCID: PMC13198467

Gale RP, Hochhaus A.: 2001–2026: LEUKEMIA celebrates 25 years of tyrosine kinase inhibitors. Leukemia (2026). https://doi.org/10.1038/s41375-026-02981-8

Hochhaus A, Talpaz M, Saglio G, Cortes JE, Hughes T, Apperley J, Hantschel O, Rea D, Schuld P, Kantarjian H: . From fatal disease to functional cure: 25 years of tyrosine kinase inhibition in chronic myeloid leukemia. Leukemia (2026). https://doi.org/10.1038/s41375-026-02984-5

Hübner, J: Gibt es Parallelen zwischen Alternativer Medizin und Postmoderne? Und was lernen wir daraus für eine gute Patientenversorgung? Jahrbuch Wissenschaftsfreiheit, Vol. 2026(2026), Iss. 3 : pp. 297–311 | First published online: May 12, 2026

Ernst P, Theis B, Franiel T: Hypoglycemia due to a hormone-secreting tumor. Dtsch Arztebl Int 2026; 123

Maschmeyer G, Fehm T, Loibl S, Dittrich R, Hilgendorf I. Onkopedia: What's New? Systemic Tumor Treatment in Pregnancy. Oncol Res Treat. 2026;49(3):134-149. doi: 10.1159/000547137. Epub 2025 Jul 2. PMID: 40602390

Kanellopoulos A, Koster L, de Lavallade H, Ortí G, Francis S, Passweg J, Apperley J, Bethge W, Rabitsch W, Clay J, Forcade E, Hurst E, Besley C, Kinsella F, Aljurf M, Huang H, Ho A, Hilgendorf I, Choi G, Ayuk F, Grzegorz H, Stelljes M, Richardson D, Morozova E, Prejzner W, Zeiser R, Armstrong C, Raj K, Drozd-Sokolowska J, Chalandon Y, McLornan DP. Management of tyrosine kinase inhibitors and donor lymphocyte infusions post transplantation for chronic myeloid leukemia: a survey of contemporary practice on behalf of the chronic malignancies working party of the EBMT. Bone Marrow Transplant. 2026 Jun;61(6):711-717. doi: 10.1038/s41409-026-02862-9. Epub 2026 Apr 10. PMID: 41963641

Massoud R, Flossdorf S, Hanke F, Schroeder T, Bethge W, Zeiser R, Pabst C, Wulf G, Sala E, Hilgendorf I, Scheid C, Edinger M, Stölzel F, Blau IW, Stelljes M, Kobbe G, Platzbecker U, Bittenbring JT, Eder M, Fleischhauer K, Burchert A, Schmid C, Kröger N. Impact of FMS-like tyrosine kinase 3 inhibitor maintenance on post-transplant outcomes in acute myeloid leukemia with FMS-like tyrosine kinase 3 mutations: a real-world German registry analysis highlighting sorafenib. Haematologica. 2026 Mar 5. doi: 10.3324/haematol.2025.300176. Epub ahead of print. PMID: 41784041

Grundherr JV, Elmers S, Samland L, Mühlberg R, Dwinger S, Baumann J, Koch B, Wolters F, Hail LA, Escherich G, Bergelt C, Jensen W, Vettorazzi E, Pinnschmidt H, Valentini L, Baumann FT, Singer S, Reer R, Metz C, Calaminus G, Faber J, Schmidt D, Langer T, Hilgendorf I, Koehler M, Puzik A, Aschhoff M, Sander A, Schiffmann L, Sokalska-Duhme M, Schuster S, Kock-Schoppenhauer AK, Smollich M, Rostock M, Bokemeyer C, Stein A, Sinn M. Dietary intervention among young cancer survivors within the CARE for CAYA program. J Cancer Surviv. 2026 Mar 26. doi: 10.1007/s11764-026-01997-4. Epub ahead of print. PMID: 41886140

Walter A, Katenkamp K, Gaßler N, Lehmann T, Weschenfelder W, Spiegel C, Hofmann GO, Malouhi A, Hochhaus A, Rinke J, Clement JH, Schrenk KG. MiRNA-based expression signatures in differential diagnosis of enchondroma and chondrosarcoma. J Bone Oncol. 2026 Apr 8;58:100761. doi: 10.1016/j.jbo.2026.100761. PMID: 42095206; PMCID: PMC13141744

Altmann E, Hübner J, Bauer-Büntzel C, Büntzel J. Implementing Instagram as educational tool for teaching hematology and medical oncology - a cross-sectional study. BMC Med Educ. 2026 May 5. doi: 10.1186/s12909-026-09350-0. Epub ahead of print. PMID: 42087121

Hauff J, Josfeld L, Hübner J. Online information for patients on cancer diets - a comparison of German- and English-language websites. BMC Med Inform Decis Mak. 2026 Apr 30;26(1):149. doi: 10.1186/s12911-026-03529-7. PMID: 42063128; PMCID: PMC13134107

Annabell Walter, Kathrin Katenkamp, Nikolaus Gaßler, Thomas Lehmann, Wolfram Weschenfelder, Christian Spiegel, Gunther O. Hofmann, Amer Malouhi, Andreas Hochhaus, Jenny Rinke, Joachim H. Clement, Karin G. Schrenk: MiRNA-based expression signatures in differential diagnosis of enchondroma and chondrosarcoma, Journal of Bone Oncology, Volume 58, 2026, 100761,ISSN 2212-1374, https://doi.org/10.1016/j.jbo.2026.100761

Hochhaus, A., le Coutre, P., Milojkovic, D. et al. ASC4OPT: asciminib treatment optimization study in patients with chronic myeloid leukemia in chronic phase previously treated with two or more tyrosine kinase inhibitors. Leukemia (2026). https://doi.org/10.1038/s41375-026-02965-8

Morath O, Wolfrum T, Crodel C, Hochhaus A, Ernst T, Rinke J. Dysregulation of HIF-1α-regulated and thrombo-inflammatory genes may contribute to thrombotic risk in patients with BCR::ABL1-negative myeloproliferative neoplasms. J Thromb Haemost. 2026 Apr 16:S1538-7836(26)00259-X. doi: 10.1016/j.jtha.2026.04.013. Epub ahead of print. PMID: 42000137

Kiefer L, Ciarlo G, Ostendorf F, Hintze E, Hübner J. Health literacy, nutrition, complementary medicine and their associations with life satisfaction in cancer patients: a cross-sectional study. BMC Cancer. 2026 Mar 13;26(1):453. doi: 10.1186/s12885-026-15848-z. PMID: 41820903; PMCID: PMC13063638

Stölzel F, Stelljes M, Beelen DW, Markiewicz M, Reményi P, Luft T, Ciceri F, Wagner-Drouet EM, Junghanss C, Scheid C, Patriarca F, Socié G, Hilgendorf I, Rambaldi A, Schaefer-Eckart K, Russo D, Wulf G, Glass B, Labussiere-Wallet H, Stuhler G, Bieniaszewska M, Casper J, Holler E, Benedetti F, Iori AP, Kunadt D, Mihajlović J, Schild B, Khan I, Li X, Bethge W. GVHD and GRFS in patients with acute myeloid leukemia undergoing allogeneic HCT with treosulfan- versus reduced-intensity busulfan-based conditioning: a subgroup analysis of a randomized phase 3 trial. Haematologica. 2026 Jan 29. doi: 10.3324/haematol.2025.288770. Epub ahead of print. PMID: 41609025

Shumilov E, Wurm-Kuczera R, Kauer J, Wang M, Mazzeo P, Boyadzhiev H, Gebauer N, Holtick U, Hölscher A, Teichert M, Nierychlewska PM, Kimmich C, Berning P, Melchardt T, Zeremski V, Wirths C, Nakov P, Schultze-Florey C, Velazquez GF, Lesan V, Krämer I, Kaiser F, Vehling-Kaiser U, Ossami-Saidy A, Huber H, Behringer A, Bentz M, Scholz JK, Gödel P, Schnetzke U, Vucinic V, Shorb E, Ghandili S, Kerkhoff A, Scheich S, Aydin S, Mayer K, Bacher U, Wille K, Glass B, Oellerich T, Ayuk F, Heidel F, Thurner L, Lutz M, Hänel M, Scholz CW, Tometten M, Pott C, Dreger P, Mougiakakos D, Dietrich S, Derenzini E, Chapuy B, Tresckow BV, Pabst T, Müller F, Lenz G. Outcomes of real-world complete responders after fixed-duration glofitamab in relapsed/refractory large B-cell lymphoma. Haematologica. 2026 Apr 2. doi: 10.3324/haematol.2025.300063. Epub ahead of print. PMID: 41924925

Cortes JE, Hughes TP, Wang J, Kim DW, Kim DDH, Mayer J, Goh YT, le Coutre P, Etienne G, Kim I, Andorsky DJ, Bombaci F, Issa GC, Takahashi N, Kapoor S, Jinwal R, Malek K, McCulloch T, Yau L, Larson RA, Hochhaus A. Asciminib demonstrates superior efficacy and safety in newly diagnosed chronic myeloid leukemia in the ASC4FIRST trial. Blood. 2026 Mar 26;147(13):1433-1446. doi: 10.1182/blood.2025029210. PMID: 41397287

Grumt A, Huchel S, Keinki C, Mathies V, Käsmann L, Huebner J. Development of an Assessment Tool for YouTube Videos With Medical Content: A Focus on Nutrition and Cancer. Integr Cancer Ther. 2026 Jan-Dec;25:15347354261422762. doi: 10.1177/15347354261422762. Epub 2026 Mar 15. PMID: 41832899

Morath O, Lindig U, Katenkamp K, Gassler N, Haziri D, Auletta V, Bauerschlag D, Franiel T, Bergener M, Griessbach AS, Ernst T, Hochhaus A, Crodel CC. Diagnostic and therapeutic challenges in claudin 18.2-positive gastric cancer treated with zolbetuximab: Intrapatient heterogeneity or secondary loss of expression? J Cancer Res Clin Oncol. 2026 Mar 19;152(3):70. doi: 10.1007/s00432-026-06447-3. PMID: 41854734; PMCID: PMC13003056

Al-Sawaf O, Stumpf J, Zhang C, Simon F, Bosch F, Feyzi E, Ghia P, Gregor M, Kater AP, Lindström V, Mattsson M, Niemann CU, Staber PB, Tadmor T, Thornton P, Wendtner CM, Janssens A, Noesslinger T, Bohn JP, da Cunha-Bang C, Poulsen CB, Ranti J, Illmer T, Schoettker B, Böttcher S, Gaska T, Vandenberghe E, Clifford R, Benjamini O, Frustaci AM, Scarfò L, Sportoletti P, Schreurs J, Levin MD, van der Straaten H, van der Klift M, Tran H, de la Serna J, Loscertales J, Lindblad O, Bergendahl Sandstedt A, Goede J, Baumann M, Fink AM, Fischer K, Ritgen M, Kreuzer KA, Schneider C, Tausch E, Stilgenbauer S, Robrecht S, Eichhorst B, Hallek M; CLL17 Trial Investigators. Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia. N Engl J Med. 2026 Mar 12;394(11):1084-1096. doi: 10.1056/NEJMoa2515458. Epub 2025 Dec 6. PMID: 41358601

Lorenzen S, Goetze TO, Thuss-Patience PC, Riera-Knorrenschild J, Goekkurt E, Dechow TN, Ettrich TJ, Hofheinz RD, Luley KB, Pink D, Lindig U, Folprecht G, Schuch G, Bitzer M, Heinemann V, Angermeier S, Bolling C, Loose M, Junge S, Pauligk C, Al-Batran SE. First-line modified FOLFOX plus/minus nivolumab and Ipilimumab or FLOT plus nivolumab in advanced gastroesophageal adenocarcinoma: a phase II multi-cohort trial. Nat Commun. 2026 Feb 27;17(1):2072. doi: 10.1038/s41467-026-69622-7. PMID: 41760643; PMCID: PMC12948978

Kreher KL, Dörfler J, Büntzel J, Büntzel J, Hübner J. Reliability of Results from Randomized Studies and Systematic Reviews in Acupuncture: A Methodological Review for Acupuncture Against Symptoms of Breast Cancer Care. In Vivo. 2026 Mar-Apr;40(2):726-747. doi: 10.21873/invivo.14234. PMID: 41760339; PMCID: PMC12949905

Tharmaseelan H, Sgonina LM, Bühnen I, Schnetzke U, Meißner J, Sellmayr M, Beverungen D, Hellmuth JC, Puthenparambil J, Zamrik T, Ferdinandus J, Shumilov E, Kerkhoff A, Melchardt T, Bröckelmann PJ, Kobe C, Borchmann P, Von Tresckow B. Anti-programmed cell death protein 1-based salvage therapy for relapsed/refractory Hodgkin lymphoma: a multicenter real-world analysis. Haematologica. 2026 Feb 26. doi: 10.3324/haematol.2025.288996. Epub ahead of print. PMID: 4174288

Lauseker M, Sacha T, Klamova H, Yakoleva J, Lomaia E, Milojkovic D, Fabisch C, Nicolini FE, Olsson-Stromberg U, Zackova D, Lewandowski K, Ernst P, Castagnetti F, Hirschbühl K, Zupan I, Voskanyan A, Gołos A, Frietsch JJ, Gil J, Faber E, Krause SW, Parry A, Saussele S, Heibl S, Franke GN, Casado LF, Paczkowska E, Hebart H, Eder M, Anhut P, Trautmann-Grill K, Szczepanek E, Südhoff T, Patkowska E, Kiani A, Ernst T, Apperley J, Mayer J, Hochhaus A, Pfirrmann M, Brioli A. Development of a prognostic scoring system for chronic myeloid leukemia in blast phase. Leukemia. 2026 Apr;40(4):751-758. doi: 10.1038/s41375-026-02875-9. Epub 2026 Feb 19. PMID: 41714405; PMCID: PMC13056570

Sitte HH, Hübner J, Aust N, Weisshäupl V, Ernst E. Trials and tribulations of responsible people trying to uphold scientific standards. Res Integr Peer Rev. 2026 Feb 16;11(1):5. doi: 10.1186/s41073-026-00191-5. PMID: 4169274

Obstfelder E, Herrmann J, Vučinić V, Hochhaus A, Schnetzke U, Eigendorff F. Tisagenlecleucel yields superior patient-reported health-related quality of life compared to autologous stem cell transplantation in patients with relapsed/refractory large B-cell lymphomas. Ann Hematol. 2026 Feb 5;105(3):88. doi: 10.1007/s00277-026-06840-5. PMID: 41639434

Voigtländer S, Dörfler J, Hübner J. Acupuncture as treatment of cancer-therapy induced fatigue: a critical systematic review with a focus on the methodological assessment of blinding. J Cancer Res Clin Oncol. 2026 Jan 8;152(1):37. doi: 10.1007/s00432-025-06395-4. PMID: 41507508; PMCID: PMC12783427

Crodel CC, Kohnle C, Radsak MP, Nückel H, Jilg S, Hochhaus A, Heidel FH, Hübner J. Patient-reported outcomes regarding the use of complementary and alternative medicine (CAM) in BCR::ABL1-negative myeloproliferative neoplasias. J Cancer Res Clin Oncol. 2026 Jan 20;152(1):41. doi: 10.1007/s00432-025-06421-5. PMID: 41559233; PMCID: PMC12819938

Fleischmann M, Hansen O, Voigtländer D, Bechwar J, Schwietzer L-J, Bahr S, et al. Targeting MCL-1 and MAPK overcomes venetoclax resistance in FLT3-ITD-positive AML cells harbouring activating PTPN11 (SHP-2) mutations. Br J Haematol. 2026; 00: 1–11. https://doi.org/10.1111/bjh.70344

Hilgendorf, I. (2025). Impfungen bei immunsupprimierten Patienten. In: Schmoll, HJ. (eds) Kompendium Internistische Onkologie. Springer Reference Medizin. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-46764-0_309-1

Ernst P, Lohse C, Lauseker M, Geißler J, le Coutre P, Brümmendorf TH, Saußele S, Burchert A, Franke GN, La Rosée P, Brioli A, Schenk T, Fabisch C, Ernst T, Mehlkop G, Hochhaus A. Treatment expectations and goals among patients with chronic myeloid leukemia in Germany: a patient-centered perspective. Leukemia. 2026 Jan;40(1):29-36. doi: 10.1038/s41375-025-02826-w. Epub 2025 Dec 19. PMID: 41419606; PMCID: PMC12789025

Bill M, Eckardt JN, Döhner K, Röhnert MA, Rausch C, Metzeler KH, Spiekermann K, Stasik S, Wurm AA, Sauer T, Scholl S, Schnetzke U, Hochhaus A, Crysandt M, Brümmendorf TH, Krug U, Wörmann B, Einsele H, Hiddemann W, Görlich D, Sauerland C, Steffen B, Neubauer A, Burchert A, Schäfer-Eckart K, Berdel WE, Schliemann C, Krause SW, Hänel M, Hanoun M, Kaufmann M, Fransecky L, Braess J, Schetelig J, Middeke JM, Bullinger L, Heuser M, Thol F, Serve H, Baldus CD, Platzbecker U, Müller-Tidow C, Válka J, Šrámek J, Weinbergerova B, Mayer J, Dumas PY, Bertoli S, Delabesse E, Récher C, Pigneux A, Herold T, Ganser A, Döhner H, Bornhäuser M, Thiede C, Röllig C. Differential prognostic impact of myelodysplasia-related gene mutations in a European cohort of 4978 intensively treated AML patients. Leukemia. 2026 Jan;40(1):63-71. doi: 10.1038/s41375-025-02781-6. Epub 2025 Oct 27. PMID: 41145671; PMCID: PMC12789037

Salmon M, Naumann N, Rinke J, Meggendorfer M, Radia D, Pomfret M, Ernst T, Hochhaus A, Reiter A, Tapper WJ, White H, Cross NCP. Long read nanopore DNA sequencing with adaptive sampling to identify tyrosine kinase fusion genes. Leukemia. 2026 Jan;40(1):37-46. doi: 10.1038/s41375-025-02801-5. Epub 2025 Nov 18. PMID: 41254115; PMCID: PMC12789007

Truger M, Meggendorfer M, Walter W, Hutter S, Alsdorf W, Massenkeil G, Martens UM, Kern W, Hörst K, Kühn C, Reiter A, Hochhaus A, Haferlach T. Solving Riddles Through Sequencing (SIRIUS): unlocking hematologic diagnoses by whole genome and transcriptome sequencing. Leukemia. 2026 Jan;40(1):55-62. doi: 10.1038/s41375-025-02820-2. Epub 2025 Dec 19. PMID: 41419605; PMCID: PMC12789012

Hochhaus A., Gale RP: 40 years of LEUKEMIA. Leukemia (2026) 40:1–2; https://doi.org/10.1038/s41375-025-02840-y

Fischer M, Büntzel J, Hübner J. Social and psychological effects of a stoma on the sexuality and self-image of patients. Int J Colorectal Dis. 2026 Jan 20;41(1):39. doi: 10.1007/s00384-026-05091-0. PMID: 41559477

Burchert A, Nicolini FE, le Coutre P, Saussele S, Hochhaus A, Tuere E, Metzelder SK, Pauck K, Garn H, Raifer H, Huber M, Gattermann N, Crysandt M, Schafhausen P, Bormann M, Radsak MP, Guerci-Bresler A, Illmer T, Goebeler ME, Herhaus P, Teichmann LL, Franke GN, Lang F, Krause SW, Möhle R, Klausmann M, Stegelmann F, Lutz C, Etienne G, Stoltefuß A, Göthert JR, Ernst T, Abu-Samra M, Höffkes HG, Neubauer A, Wang Y, Weiland P, Otto C, Kiessler L, Weber T, Kroning L, Nist A, Stiewe T, Hehlmann R, Aminossadati B, Wittenberg M, Winterstein K, Oellerich T, Lechner M, Pfirrmann M, Schade-Brittinger C, Klemm P, Michel C. Randomized phase 3 trial of Ropeginterferon alfa-2b versus surveillance after tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia (ENDURE/CML-IX). Leukemia. 2026 Feb;40(2):410-417. doi: 10.1038/s41375-025-02859-1. Epub 2026 Jan 12. PMID: 41526617; PMCID: PMC12875868

Witt, N., Mathies, V. Ernährung in der Prähabilitation. Onkologie (2026). https://doi.org/10.1007/s00761-025-01896-w

Anika Wolff, Jutta Hübner, Jens Büntzel and Judith Büntzel: “Psychotropic Medicinal Plant Use in Oncology: A Dual-Cohort Analysis and Its Implications for Anesthesia and Perioperative Care”, Appl. Sci. 2026, 16(1), 481; https://doi.org/10.3390/app16010481

Dendorfer SM, Schmidt-Brücken K, Kramer M, Steffen B, Schliemann C, Mikesch JH, Alakel N, Herbst R, Hänel M, Hanoun M, Kaufmann M, Weinbergerova B, Schäfer-Eckart K, Sauer T, Neubauer A, Burchert A, Baldus CD, Mertová J, Jost E, Niemann D, Novák J, Krause SW, Scholl S, Hochhaus A, Held G, Szotkowski T, Rank A, Schmid C, Fransecky L, Kayser S, Schaich M, Fiebig F, Haake A, Schetelig J, Middeke JM, Stölzel F, Platzbecker U, Thiede C, Müller-Tidow C, Berdel WE, Ehninger G, Mayer J, Serve H, Bornhäuser M, Röllig C. Randomized Comparison of Cardiotoxicity With 60 Versus 90 mg Daunorubicin in AML Induction Therapy. Am J Hematol. 2026 Mar;101(3):512-520. doi: 10.1002/ajh.70160. Epub 2026 Jan 5. PMID: 41492073; PMCID: PMC12869000

Schenk T, Fabisch C, Ernst T, Ernst P, Saussele S, Žáčková D, Mayer J, Klamová H, Hochhaus A; German CML Study Group and the Czech Leukemia Study Group. Ponatinib for CML patients in routine clinical practice: the PONDEROSA study. Ann Hematol. 2026 Jan 15;105(1):9. doi: 10.1007/s00277-026-06788-6. PMID: 41535610; PMCID: PMC12804319